Molecular characteristics and predictors of survival in patients with malignant neuroendocrine tumors

International Journal of Cancer

Volumn 123, Issue 7, 2008, Pages 1556-1564

  Arnold, Christian N ^a   Nagasaka, Takeshi ^b   Goel, Ajay ^b   Scharf, Iris ^a   Grabowski, Patricia ^c   Sosnowski, Andrea ^a   Schmitt Gräff, Annette ^a   Boland, C Richard ^b   Arnold, Rudolf ^d   Blum, Hubert E ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

CpG island methylation; Fore ; Hindgut tumors; Loss of heterozygosity; Microsatellite instability; Midgut tumors; Neuroendocrine tumors; Promoter methylation

Indexed keywords

KI 67 ANTIGEN; MICROSATELLITE DNA; TUMOR MARKER;

ADULT; AGED; ARTICLE; BENIGN TUMOR; CANCER LOCALIZATION; CANCER PATIENT; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL FEATURE; COLORECTAL CANCER; CPG ISLAND; FEMALE; HUMAN; HUMAN TISSUE; MALE; MALIGNANT NEOPLASTIC DISEASE; METHYLATION; MICROSATELLITE INSTABILITY; MIDGUT; NEUROENDOCRINE TUMOR; ONCOGENE; OUTCOME ASSESSMENT; P16 GENE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; TUMOR DIFFERENTIATION; CELL DIFFERENTIATION; CHROMOSOME MAP; COLORECTAL TUMOR; DNA METHYLATION; GENETICS; GENOMIC INSTABILITY; HETEROZYGOSITY LOSS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MORTALITY; PATHOLOGY; POLYMERASE CHAIN REACTION; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; CHROMOSOME MAPPING; COLORECTAL NEOPLASMS; DNA METHYLATION; FEMALE; GENOMIC INSTABILITY; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; NEUROENDOCRINE TUMORS; POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 50549094426     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23690     Document Type: Article

References (43)

1. Öberg K. Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment. Curr Opin Oncol 2002;14:38-45. 2002;14:38-45.
2. Klöppel G, Perren A, Heitz PU. The gastroenteropancreatic neuroendocrine cell system and its tumors: the WHO classification. Ann N Y Acad Sci 2004;1014:13-27.
3. Hipfner DR, Cohen SM. Connecting proliferation and apoptosis in development and disease. Nat Rev Mol Cell Biol 2004;5:805-15.
4. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997;386:623-710.
5. Loeb LA. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 1991;51:3075-9.
6. Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D, Compton C, Mayer RJ, Goldberg R, Bertagnolli MM, Boland CR. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology 2007;132:127-38.
7. Issa JP, Baylin SB. Epigenetics and human disease. Nat Med 1996;2:281-2.
8. Lengauer C, Kinzler KW, Vogelstein B. DNA methylation and genetic instability in colorectal cancer cells. Proc Natl Acad Sci USA 1997;94:2545-50.
9. Goel A, Arnold CN, Niedzwiecki D, Chang DK, Ricciardiello L, Carethers JM, Dowell JM, Wasserman L, Compton C, Mayer RJ, Bertagnolli MM, Boland CR. Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res 2003;63:1608-14.
10. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-96.
11. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004;4:988-93.
12. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-9.
13. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, Korner M, Lopes JM, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006;449:395-401.
14. Rindi G, Kloppel G, Couvelard A, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2007;451:757-62.
15. Onaitis MW, Kirshbom PM, Hayward TZ, Quayle FJ, Feldman JM, Seigler HF, Tyler DS. Gastrointestinal carcinoids: characterization by site of origin and hormone production. Ann Surg 2000;232:549-56.
16. Moyana TN, Xiang J, Senthilselvan A, Kulaga A. The spectrum of neuroendocrine differentiation among gastrointestinal carcinoids: importance of histologic grading. MIB-1, p53, and bcl-2 immunoreactivity. Arch Pathol Lab Med 2000;124:570-6.
17. Grabowski P, Griss S, Arnold CN, Hörsch D, Göke R, Arnold R, Heine B, Stein H, Zeitz M, Scherübl H. Nuclear survivin is a powerful novel prognostic marker in gastroenteropancreatic neuroendocrine tumor disease. Neuroendocrinology 2005;81:1-9.
18. Arnold CN, Sosnowski A, Schmitt-Graff A, Arnold R, Blum HE. Analysis of molecular pathways in sporadic neuroendocrine tumors of the gastro-entero- pancreatic system. Int J Cancer 2007;120:2157-64.
19. Chan AO, Kim SG, Bedeir A, Issa JP, Hamilton SR, Rashid A. CpG island methylation in carcinoid and pancreatic endocrine tumors. Oncogene 2003;22:924-34.
20. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-57.
21. Terris B, Meddeb M, Marchio A, Danglot G, Flejou JF, Belghiti J, Ruszniewski P, Bernheim A. Comparative genomic hybridization analysis of sporadic neuroendocrine tumors of the digestive system. Genes Chromosomes Cancer 1998;22:50-6.
22. Tonnies H, Toliat MR, Ramel C, Pape UF, Neitzel H, Berger W, Wiedenmann B. Analysis of sporadic neuroendocrine tumours of the enteropancreatic system by comparative genomic hybridisation. Gut 2001;48:536-41.
23. Amarapurkar AD, Davies A, Ramage JK, Stangou AJ, Wight DG, Portmann BC. Proliferation of antigen MIB-1 in metastatic carcinoid tumours removed at liver transplantation: relevance to prognosis. Eur J Gastroenterol Hepatol 2003;15:139-43.
24. Arnold R, Rinke A, Klose KJ, Muller HH, Wied M, Zamzow K, Schmidt C, Schade-Brittinger C, Barth P, Moll R, Koller M, Unterhalt M, et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 2005;3:761-71.
25. Rindi G, D'Adda T, Froio E, Fellegara G, Bordi C. Prognostic factors in gastrointestinal endocrine tumors. Endocr Pathol 2007;18:145-9.
26. Shimizu T, Tanaka S, Haruma K, Kitadai Y, Yoshihara M, Sumii K, Kajiyama G, Shimamoto F. Growth characteristics of rectal carcinoid tumors. Oncology 2000;59:229-37.
27. Grabowski P, Schindler I, Anagnostopoulos I, Foss HD, Riecken EO, Mansmann U, Stein H, Berger G, Buhr HJ, Scherübl H. Neuroendocrine differentiation is a relevant prognostic factor in stage III-IV colorectal cancer. Eur J Gastroenterol Hepatol 2001;13:405-11.
28. Grabowski P, Sturm I, Schelwies K, Maaser K, Buhr HJ, Dorken B, Zeitz M, Daniel PT, Scherübl H. Analysis of neuroendocrine differentiation and the p53/BAX pathway in UICC stage III colorectal carcinoma identities patients with good prognosis. Int J Colorectal Dis 2006;21:221-30.
29. Lubomierski N, Kersting M, Bert T, Muench K, Wulbrand U, Schuermann M, Bartsch D, Simon B. Tumor suppressor genes in the 9p21 gene cluster are selective targets of inactivation in neuroendocrine gastroenteropancreatic tumors. Cancer Res 2001;61:5905-10.
30. Perren A, Komminoth P, Saremaslani P, Matter C, Feurer S, Lees JA, Heitz PU, Eng C. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. Am J Pathol 2000;157:1097-103.
31. Perren A, Saremaslani P, Schmid S, Bonvin C, Locher T, Roth J, Heitz PU, Komminoth P. DPC4/Smad4: no mutations, rare allelic imbalances, and retained protein expression in pancreatic endocrine tumors. Diagn Mol Pathol 2003;12:181-6.
32. Perren A, Schmid S, Locher T, Saremaslani P, Bonvin C, Heitz PU, Komminoth P. BRAF and endocrine tumors: mutations are frequent in papillary thyroid carcinomas, rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors. Endocr Relat Cancer 2004;11:855-60.
33. Perren A, Komminoth P, Heitz PU. Molecular genetics of gastroenteropancreatic endocrine tumors. Ann N Y Acad Sci 2004; 1014:208.
34. Serrano J, Goebel SU, Peghini PL, Lubensky IA, Gibril F, Jensen RT. Alterations in the p16INK4a/CDKN2A tumor suppressor gene in gastrinomas. J Clin Endocrinol Metab 2000;85:4146-56.
35. Tannapfel A, Vomschloss S, Karhoff D, Markwarth A, Hengge UR, Wittekind C, Arnold R, Horsch D. BRAF gene mutations are rare events in gastroenteropancreatic neuroendocrine tumors. Am J Clin Pathol 2005;123:256-60.
36. Wild A, Ramaswamy A, Langer P, Celik I, Fendrich V, Chaloupka B, Simon B, Bartsch DK. Frequent methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene in pancreatic endocrine tumors. J Clin Endocrinol Metab 2003;88:1367-73.
37. Furlan D, Cerutti R, Uccella S, La RS, Rigoli E, Genasetti A, Capella C. Different molecular profiles characterize well-differentiated endocrine tumors and poorly differentiated endocrine carcinomas of the gastroenteropancreatic tract. Clin Cancer Res 2004;10:947-57.
38. Grabowski P, Schönfelder J, Ahnert-Hilger G, Foss HD, Heine B, Schindler I, Stein H, Berger G, Zeitz M, Scherübl H. Expression of neuroendocrine markers: a signature of human undifferentiated carcinoma of the colon and rectum. Virchows Arch 2002;441:256-63.
39. Modlin IM, Kidd M, Latich I, Zikusoka MN, Shapiro MD. Current status of gastrointestinal carcinoids. Gastroenterology 2005;128:1717-51.
40. Hommura F, aka-Akita H, Mishina T, Nishi M, Kojima T, Hiroumi H, Ogura S, Shimizu M, Katoh H, Kawakami Y. Prognostic significance of p27KIP1 protein and ki-67 growth fraction in non-small cell lung cancers. Clin Cancer Res 2000;6:4073-81.
41. Toliat MR, Berger W, Ropers HH, Neuhaus P, Wiedenmann B. Mutations in the MEN I gene in sporadic neuroendocrine tumours of gastroenteropancreatic system. Lancet 1997;350:1223.
42. Ghimenti C, Tannergard P, Wahlberg S, Liu T, Giulianotti PG, Mosca F, Fornaciari G, Bevilacqua G, Lindblom A, Caligo MA. Microsatellite instability and mismatch repair gene inactivation in sporadic pancreatic and colon tumours. Br J Cancer 1999;80:11-16.
43. Kidd M, Eick G, Shapiro MD, Camp RL, Mane SM, Modlin IM. Microsatellite instability and gene mutations in transforming growth factor-beta type II receptor are absent in small bowel carcinoid tumors. Cancer 2005;103:229-36.